Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series
Charissa J Patricelli1, Jessie Chai, Shanlea Gordon
1From the Families in Recovery (FIR) Unit, BC Women's Hospital and Health Centre, Vancouver, BC, Canada (CJP, SG, IJG, NC, KS, VP); Women's Health Research Institute, Vancouver, BC, Canada (CJP, JC, SG, IJG, KU, AA); Department of Family Practice, University of British Columbia, Vancouver, BC, Canada (CJP); University of British Columbia Faculty of Medicine, Vancouver BC, Canada (JC); Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada (AA); Department of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada (KU).
Objectives:
Untreated opioid use disorder (OUD) in pregnancy may lead to adverse outcomes for the individual and fetus. Injectable opioid agonist therapy (iOAT) is the highest intensity treatment for severe refractory OUD currently available; however, research on perinatal administration is limited. We present the first known case series of 13 pregnant or postpartum participants who received intravenous hydromorphone while admitted to the Families in Recovery (FIR) unit, an in-patient perinatal stabilization unit in Canada.
Methods:
Patients who received iOAT at FIR between 2019 and 2022 were invited to participate. Prospectively enrolled participants completed a self-report sociodemographics and exposures survey. Medical/social backgrounds of participants at admission, iOAT and other opioid agonist therapy administration, and health/social outcomes of mother and infant at discharge were collected on all participants via retrospective maternal and infant medical chart review.
Results:
Participants initiated iOAT while pregnant (n = 5) or postpartum (n = 8) and received iOAT for 23 days on average. At discharge, 8 participants underwent planned transition to community with infant in their care and a discharge plan including outpatient prescriptions, housing arrangements, follow-up appointments, and supportive programming. All infants received oral morphine after delivery and were discharged in good health.
Conclusions:
This is the first known case series of iOAT administration in the peripartum. The cases illustrate iOAT as an option that can achieve OUD stabilization in perinatal individuals to support patient engagement and retention in care.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
01:29Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:25Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
01:24Parenteral Anesthetics: Overview
01:22Routes of Drug Administration: Overview
Enteral administration refers to drugs absorbed through the gastrointestinal tract. They can be swallowed (perorally), placed under the tongue (sublingually), or on the inner lining of the cheeks (buccally). Perorally administered drugs take time to be absorbed and have a slower onset of action. The rectal route is another form of enteral administration, which allows for...